Sleep disturbances after endocrine therapy in women with breast cancer
Keywords:
breast cancer, sleep disorder, quality of lifeAbstract
Introduction: Endocrine therapy is a standard treatment for women with breast cancer. It can cause sleep disturbances that affect women's normal functioning. Objective: The aim of the present study is to analyze the results of the questions related to sleep disturbances and the results of the physical, role and emotional functioning scales in women with breast cancer undergoing hormonal therapy. Materials and Methods: The results of 210 women are presented. A demographic questionnaire and a quality of life questionnaire were used. Excel and SPSS v26 were used for statistical analysis and data processing. Results and Discussion: Over 2/3 of the respondents reported sleep disorders – 72%. A moderate correlation was found between the results for sleep problems and physical function at (r = 0.358, p = 0.000); insomnia and poor sleep quality adversely affect the performance of normal daily activities. A moderate correlation was observed between sleep disorders and emotional function (r = 0.349, p = 0.000). Sleep problems correlated moderately with role functioning (r = 0.343, p = 0.000). Conclusion: Sleep disturbance is a serious challenge for women undergoing hormonal therapy for breast cancer. Timely assessment of insomnia symptoms is necessary to gain an understanding of the problem and implement the necessary therapy.
References
Howlader N, Noone A, Krapcho M et al. SEER cancer statistics review. 2019; 1975-2016.
Burstein HJ, Lacchetti C, Anderson H et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression J Clin Oncol, 2016; 34:1689-1701.
Cuzick J, Sestak I, Baum M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Lancet Oncol, 2010; 11:1135-1141. doi:10.1016/S1470-2045(10)70257-6.
Curigliano G, Burstein HJ, Winer EP et al. De-escalating and escalating treatments for early-stage breast cancer: the st. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017 Ann Oncol, 2017; 28:1700-1712, doi:10.1093/annonc/mdx308.
Mouridsen H, Giobbie A, Hurder A et al. Coates BIG 1-98 collaborative group, letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med, 2009; 361:766-776. doi:10.1056/NEJMoa0810818.
Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update J Clin Oncol, 2019; 37:423-438. doi:10.1200/JCO.18.01160.
Yeo SM, Lim JY, Kim SW et al. Impact of Adjuvant Hormone Therapy on Sleep, Physical Activity, and Quality of Life in Premenopausal Breast Cancer: 12-Month Observational Study. J Breast Cancer. 2023; 26(2):93-104. doi: 10.4048/jbc.2023.26.e11.
Savard J, Ivers H, Morin CM et al. Cancer treatments and their side effects are associated with aggravation of insomnia: results of a longitudinal study Cancer, 2015, 121:1703-1711. doi:10.1002/cncr.29244.
Park JY, Lee SK, Bae SY et al. Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors J Korean Surg Soc, 2013, 85:205-211, doi:10.4174/jkss.2013.85.5.205.
Buijs C, de Vries EGE, Mourits MJE, Willemse PHB. The influence of endocrine treatments for breast cancer on health-related quality of life Cancer Treat Rev, 2008, 34:640-655. doi:10.1016/j.ctrv.2008.04.001.
Savard J, Davidson JR, Ivers H et al. The association between nocturnal hot flashes and sleep in breast cancer survivors J Pain Symptom Manag, 2004, 27:513-522. doi:10.1016/j.jpainsymman.2003.10.013.
Ganz PA, Cecchini RS, Julian TB et al. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial Lancet, 2016, 387:857-865.
Kidwell KM, Harte SE, Hayes DF et al. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy Cancer, 2014, 120:2403-2411.
Henry NL, Azzouz F, Desta Z et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer, 2012.
Palesh O, Zeitzer JM, Conrad A et al. Vagal regulation, cortisol, and sleep disruption in women with metastatic breast cancer J Clin Sleep Med, 2008, 4:441-449.
Savard J, Morin CM. Insomnia in the context of cancer: a Review of a neglected problem J Clin Oncol, 2001, 19:895 908, doi:10.1200/JCO.2001.19.3.895.
Ancoli-Israel S. Sleep disturbances in cancer: a Review Sleep Med Res, 2015, 6. doi:10.17241/smr.2015.6.2.45.
Gabra, RH, Hashem, DF Sleep disorders and their relationship to other psychiatric disorders in women with breast cancer: a case-control study. Middle East Curr Psychiatry, 2021, 28(10). https://doi.org/10.1186/s43045-021-00090-z.
Ford ES, Cunningham TJ, Giles WH, Croft JB. Trends in insomnia and excessive daytime sleepiness among US adults from 2002 to 2012 Sleep Med, 2015, 16:372-378.
Palesh O, Aldridge-Gerry A, Zeitzer JM et al. Actigraphy- measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep, 2014; 37(5):837e42
Harris B, Ross J, Sanchez-Reilly S. sleeping in the arms of cancer: a review of sleeping disorders among patients with cancer. Cancer J. 2014; 20(5):299-305.
Ancoli-Israel, Liu L, Marler M, Parker, BA et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer FACT-B: functional assessment of cancer therapy-breast. FOSQ: functional outcome of sleep questionnaire. MFSI-SF: multidimensional fatigue symptom inventory-short form. PSQI: pittsburgh sleep quality index Support Care Canc, 2006, 14:201-202.
Bower JE. Behavioral symptoms in breast cancer patients and survivors: fatigue, insomnia, depression, and cognitive disturbance Julienne J Clin Oncol, 2008, 26:768-777.
Hajj A, Hachem R, Khoury R et al. Clinical and Genetic Factors Associated With the Breast Cancer-Related Sleep Disorders: The “CAGE-Sleep” Study–A Cross-Sectional Study, Journal of Pain and Symptom Management, 2021;62(3):e46-e55, https://doi.org/10.1016/j.jpainsymman.2021.02.022.
Angford DJ, Lee K, Miaskowski C. Sleep disturbance interventions in oncology patients and family caregivers: a comprehensive review and meta-analysis. Sleep Med Rev 2012;16(5):397-414.
Win MR, Olmstead RE, Ganz PA, Haque R. Sleep disturbance, inflammation and depression risk in cancer survivors. Brain Behav Immun, 2013; 30(Suppl):S58-S67.
Cano A. Control emocional, estilo represivo de afrontamiento y cáncer: Ansiedad y cáncer. Psicooncología, 2005; 2(1):71-80.
Rand KL, Otte JL, Flockhart D et al. Modeling hot flushes and quality of life in breast cancer survivors, Climacteric, 2011; 14:1, 171-180.
Hayley MC, Williams LJ, Kennedy GA et al. Prevalence of excessive daytime sleepiness in a sample of the Australian adult population. Sleep Med 15(3):348-354
Polo-Kantola P. Sleep problems in midlife and beyond. Maturitas. 2011;68(3):224-32.
Blumel JE, Cano A, Mezones-Holguin E et al. A multinational study of sleep disorders during female mid-life. Maturitas. 2012;72(4):359-66.
Pengo MF, Won CH, Bourjeily G. Sleep in women across the life span. CHEST. 2018;154(1):196-206.
Hachul De Campos H, Brando LC, D‘Almeida V et al. Sleep disturbances, oxidative stress and cardiovascular risk parameters in postmenopausal women complaining of insomnia. Climacteric. 2006;9(4):312-9.
Silva BH, Martinez D, Wender MCO. A randomized, controlled pilot trial of hormone therapy for menopausal insomnia. Arch Women’s Mental Health. 2011;14(6):505-8.
Whiteley J, Bushmakin A, Racketa J et al. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Menopause. 2013;20(5):518-24.
Avis NE, Crawford SL, Greendale G et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Inter Med. 2015;175(4):531.
Holloway D. Managing the menopause: symptoms, consequences and treatment. Prim Health Care. 2016;26(7):40-9.
Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000;92:994-1000.
Innominato PF, Levi FA, Bjarnason GA. Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev 2010;62:979-1001.
Palesh O, Peppone L, Innominato PF et al. Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nat Sci Sleep 2012;4:151-162.
Palesh O, Aldridge-Gerry A, Zeitzer J et al. Actigraphy measured sleep disruption as a predictor of survival among women with advanced breast cancer [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 9532.
Lorizio W, Wu AH, Beattie MS et al. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat, 2012;132:1107-1118.
Savard J, Ivers H. The initiation of chemotherapy, but not radiation therapy, coincides with increased insomnia. Psychooncology, 2012;21:37-38.
Palesh O, Peppone L, Innominato PF et al. Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nat Sci Sleep, 2012;4:151-162.
Vargas S, Wohlgemuth WK, Antoni MH et al. Sleep dysfunction and psychosocial adaptation among women undergoing treatment for non-metastatic breast cancer. Psychooncology, 2010;19:669-673.
Ancoli-Israel S, Liu L, Marler MR et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer, 2006;14:201-209.
Berger AM, Farr LA, Kuhn BR et al. Values of sleep/wake, activity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer chemotherapy. J Pain Symptom Manage, 2007;33:398-409.
Phillips KM, Jim HS, Donovan KA et al. Characteristics and correlates of sleep disturbances in cancer patients. Support Care Cancer 2012;20:357-365.
Berger AM, Kuhn BR, Farr LA et al. One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue. J Clin Oncol. 2009;27:6033-6040.
Grayson S, Sereika S, Harpel C et al. Factors associated with sleep disturbances in women undergoing treatment for early-stage breast cancer. Support Care Cancer, 2022; 30:157-166. https://doi.org/10.1007/s00520-021-06373-9.
Fortner BV, Stepanski EJ, Wang SC et al. Sleep and Quality of Life in Breast Cancer Patients, Journal of Pain and Symptom Management, 2002; 24(5):471-480, https://doi.org/10.1016/S0885-3924(02)00500-6.
Desai K, Mao JJ, Su I et al. Gehrman Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors Support Care Cancer, 2013; 21:43-51, doi:10.1007/s00520-012-1490-z.
Savard J, Liu L, Natarajan L et al. Breast cancer patients have progressively impaired sleep-wake activity rhythms during chemotherapy Sleep, 2009; 32:1155-1160, doi:10.1093/sleep/32.9.1155.
Mystakidou K, Parpa E, Tsilika E et al. Sleep quality in advanced cancer patients. J Psychosom Res, 2007; 62:527e533.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Bulgarian Medical Journal (Български медицински журнал / Bulgarian Medical Journal)
